---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-103983"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:31:09.743895+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines Q2 net loss $247.8M; advances Phase 3 RAS trials; $2B Royalty Pharma deal

## Summary
- Net loss $247.8M vs $133.2M YoY; R&D expenses rose to $224.1M; FY2025 net loss guidance $1.03B-$1.09B.
- FDA Breakthrough Therapy Designation for daraxonrasib (KRAS G12C PDAC) and elironrasib (KRAS G12C NSCLC).
- Entered $2B flexible funding agreement with Royalty Pharma; first $250M tranche received; cash $2.1B.
- RASolute 302 Phase 3 trial for PDAC enrollment to complete this year; data readout expected 2026.
- Plans to initiate registrational trials for first-line PDAC and adjuvant PDAC in 2025; Phase 3 for first-line NSCLC in 2026.

## SEC filing metadata
- accession: 0000950170-25-103983
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000095017025103983/0000950170-25-103983-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000095017025103983/rvmd-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-103983
- JSON: https://secwatch.observer/filing/0000950170-25-103983.json
- Plain text: https://secwatch.observer/filing/0000950170-25-103983.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.